Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AxoGen Inc Announces Exercise Of Over-Allotment Option

Wednesday, 11 Sep 2013 06:20am EDT 

AxoGen Inc announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 184,332 shares. The total gross proceeds to AxoGen from this offering, including from the exercise of the over-allotment option, are expected to be $18.6 million, excluding deductions for underwriting discounts and commissions and estimated expenses. AxoGen will use the net proceeds from the offering to expand product commercialization and marketing efforts for its portfolio of peripheral nerve repair products (Avance Nerve Graft, AxoGuard Nerve Connector and AxoGuard Nerve Protector); to further develop its product pipeline; and for general working capital purposes. 

Company Quote

-0.09 -2.58%
12:19pm EST